Indivior Pharmaceuticals Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Indivior Pharmaceuticals Inc 's ROA in the third quarter of 2026?
Indivior Pharmaceuticals Inc achieved a return on average assets (ROA) of 36.75 % in its third quarter of 2026, this is above INDV's average return on assets of 12.86%.
Indivior Pharmaceuticals Inc assets over the 12 months ending in its third quarter of 2026 are valued at $1,227 million

ROA has improved compared to 28.37% in the second quarter of 2026, due to net income growth.

However, within the Healthcare sector 27 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 244, from total ROA ranking in the second quarter of 2026 at 383.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	-7.84 %	-16.94 %	-12.95 %	-33.87 %	-56.13 %
Y / Y Net Income Change	226.19 %	577.78 %	89.36 %	390.48 %	90.91 %
Net Income (TTM) in million	451	356	252	210	128
Return On Assets (TTM)	36.75 %	28.37 %	19.14 %	15.43 %	8.45 %
INDV's Total Ranking	# 244	# 383	# 668	# 866	# 2660
Total Assets (TTM) in million	1,305	1,206	1,197	1,201	1,416
Seq. Total Assets Change	8.21 %	0.75 %	-0.33 %	-15.18 %	-2.48 %
Seq. Net Income Change	12.3 %	37.08 %	-13.59 %	145.24 %	133.33 %

INDV's 5 Years Annual ROA >> Back to INDV Management Effectiveness >> Compare INDV ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 15
Sector	# 28
Overall	# 99

Return On Assets Statistics
High	Average	Low
36.35 %	12.86 %	-0.44 %
(Sep 30 2026)		(Mar 31 2025)

Financial Statements
Indivior Pharmaceuticals Inc 's Assets	$ 1,305 million	INDV's Balance sheet
Indivior Pharmaceuticals Inc 's Income	$ 137 million	Quarterly INDV's Income Statement
INDV's Income by Division		See INDV's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	FY	FY
Y / Y Total Assets Change	-22.17 %	-48.77 %	-	-	-
Total Assets in million	1,148	1,475	2,879	0	0
Y / Y Net Income Change	10400 %	0 %	-	-	-
Net Income in million	210	2	2	0	0
Annual Return On Assets	18.29 %	0.14 %	0.07 %	-	-

INDV's 5 Years Annual ROA >> Back to INDV Management Effectiveness >> Compare INDV ROA to its Competitors

Comment on INDV's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 18.29 % compared to prior year, due to annual net income growth of 10400 % to $210.00 million, and due to decline of value in Indivior Pharmaceuticals Inc 's assets by -22.17 % to $1,148.00 million, compared to $1,148.00 a year before.

More Return On Assets Ratios
INDV's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
INDV's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for INDV's Competitors
Subscribers only: Roa for Indivior Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for INDV's Customers

You may also want to know
INDV's Roi	INDV's Inventory Turnover Ratio	INDV's Growth Rates	INDV's Dividend Comparisons
	INDV's Profitability Ratios	INDV's Asset Turnover Ratio	INDV's Dividend Growth
INDV's Roe	INDV's Valuation Ratios	INDV's Financial Strength Ratios	INDV's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector	ROA
Exelixis Inc	63.88 %
Rigel Pharmaceuticals Inc	59.56 %
Alnylam Pharmaceuticals Inc	46.08 %
Ironwood Pharmaceuticals inc	42.53 %
Aurinia Pharmaceuticals Inc	40.63 %
Nurix Therapeutics Inc	38.61 %
Indivior Pharmaceuticals Inc	36.35 %
Rallybio Corporation	34.55 %
Idexx Laboratories Inc	34.05 %
Zevra Therapeutics Inc	26.33 %
Caredx Inc	25.74 %
Medpace Holdings Inc	24.47 %
Acadia Pharmaceuticals Inc	21.60 %
Standard Biotools Inc	21.56 %
Eli Lilly And Company	21.24 %
Iradimed Corporation	20.89 %
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %
Intuitive Surgical Inc	14.71 %
Vertex Pharmaceuticals Inc	14.16 %
Neurocrine Biosciences Inc	13.69 %
Illumina Inc	13.43 %

Date modified: 2026-10-30T13:13:54+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.